| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10550221 | Journal of Chromatography B | 2005 | 4 Pages |
Abstract
A new HPLC procedure for the determination of deracoxib, a selective cyclooxygenase-2 inhibitor, has been developed and validated. Following a liquid-liquid extraction using isopropyl alcohol and chloroform, samples were separated by isocratic reversed-phase HPLC on an Atlantis C18 column and quantified using UV detection at 252Â nm. The mobile phase was a mixture of 10Â mM potassium phosphate (pH 4.5) and acetonitrile, with a flow-rate of 1.0Â ml/min. The procedure produced a linear curve over the concentration range 10-1500Â ng/ml. The development of the assay allowed the determination of pharmacokinetic parameters after oral administration of deracoxib in cats and would be suitable for other pharmacokinetic studies.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Sherry K. Cox, Jacob Roark, Adam Gassel, Karen Tobias,